Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Omya has rebuilt and expanded its calcium carbonate production plant in Orgon, France, creating a substantially higher capacity for its functionalized calcium carbonate product platform, a new packaging line and an on-site warehouse.
read more
Sorrel Medical announced the opening of a new manufacturing facility with state-of-the-art cleanroom facilities to accommodate manufacturing scalability of its wearable drug delivery devices.
read more
Vetter has invested in additional capacity to meet that growing global demand with the purchase of a clinical manufacturing site located in Austria.
read more
Orchard Therapeutics and MolMed have extended their collaboration – initiated in April 2018 – for a period of five years through June 2025.
read more
The CCMI at the NUI Galway and Sexton Biotechnologies announced the approval by an EU Regulatory Authority of a protocol for the manufacture of allogeneic bone marrow MSCs to be given intravenously to high-risk corneal transplant recipients in the ...
read more
The FDA has been determining the safest and most appropriate time to resume prioritized domestic inspections of FDA-regulated facilities and other associated activities since we first announced postponement in March.
read more
Ovid and Angelini Pharma have announced an agreement in which Angelini will be responsible to develop, manufacture and commercialize OV101 (gaboxadol).
read more
AGC Biologics is partnering with clinical-stage biotech company Molecular Partners to develop a new class of custom-built protein therapeutics known as DARPin.
read more
Cobra has successfully produced and supplied two further DNA plasmids for the production of CombiGene’s gene therapy drug candidate CG01.
read more
Angelini Pharma will be responsible to develop, manufacture and commercialize OV101 for the potential treatment of Angelman syndrome.
read more
Cipla has received final approval for its ANDA for Icatibant Injectable 30mg/3mL from the FDA.
read more
Catalent will provide development, manufacturing and commercialization services for lenzilumab, Humanigen’s anti-human GM-CSF monoclonal antibody.
read more
SCA Pharma plans to expand its sterile pharmaceutical manufacturing facility in Windsor by 40 percent.
read more
Lantern Pharma announced agreements with contract manufacturing companies for process development and manufacturing for two of Lantern's oncology drug candidates, LP-300 and LP-184.
read more
The company is now supporting more than 200 of these projects globally.
read more